TerraPower and Cardinal Health announce manufacturing and distribution agreement for Actinium-225

08/12/2021

Cardinal Health is pleased to announce an agreement with TerraPower that will help advance the next generation of cancer treatment. Working together, the companies will develop and produce Actinium-225, which will be utilized in drug trials involving targeted alpha therapy for diseases such as breast, prostate, colon and neuroendocrine cancers, melanoma and lymphoma.

Tags: < Partnership

TerraPower and Cardinal Health announce manufacturing and distribution agreement for Actinium-225

Related Industries

Azurity Pharmaceuticals Acquires KKR-backed Slayback Pharma

Abbott Completes Acquisition of Bigfoot Biomedical

Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.

BD Ranks in Top 10 for Transparency, Awarded Best Code of Conduct in 2023 U.S. Transparency Awards

Celanese Announces Agreement with the Population Council for Sustained Release Dual-API Therapeutic

Thermo Fisher Scientific and National Minority Quality Forum Collaborate to Make Clinical Research More Accessible to Historically Underserved Communities

Carrier Named One of America’s Greenest Companies 2024 by Newsweek

Mastercard SpendingPulse: U.S. Retail Sales Expected to Grow 3.7%* This Holiday Season

Barclays appoints Pedro Costa as Vice Chairman, Technology, Media, and Telecommunications (TMT) M&A in the Americas

FairPrice Group and ExxonMobil join forces to raise more than S$100,000 for Children’s Aid Society in annual charity car wash

First HP Work Relationship Index Shows Majority of People Worldwide Have an Unhealthy Relationship with Work

chevron acquires majority stake in the advanced clean energy storage hydrogen project in delta, utah

Enabling low-carbon ammonia: our landmark agreement with CF Industries

Lucy Fato to Assume Role of Vice Chair at AIG

Georgia Tech and Hyundai Motor Group Sign MoU for Future Mobility Collaboration

MENU

CONTACT US